PhD | Director Therapeutic Innovation and BaseLaunch
Tel. +41 61 295 50 17stephan. emmerth@baselarea. swiss
The Basel-based pharmaceutical company Novartis is expanding its clinical collaboration with U.S. company Allergan. This will bring together the resources of both companies to fight the liver disease non-alcoholic steatohepatitis (NASH).
According to a press release, Novartis and Allergan are working together to develop a treatment method for NASH, which is a progressive form of non-alcoholic fatty liver disease. The intention is to conduct a Phase IIb study as part of the collaboration. This will involve the combination of a Novartis FXR agonist and Allergan’s cenicriviroc (CVC).
“We believe that collaboration is key to developing the best possible treatments that are urgently needed for NASH patients,” says Vas Narasimhan, Global Head, Drug Development and Chief Medical Officer of Novartis, quoted in the press release. NASH is a major cause of liver disease worldwide and the leading reason for liver transplants in the USA in those under the age of 50. There are currently no approved treatments for NASH.
In 2016, Novartis announced an exclusive option for a collaboration and licence agreement with Conatus Pharmaceuticals, which also related to a treatment method for NASH. Through these two collaborations, Novartis intends to develop new therapies in chronic liver diseases.